ABBO News

Ozempic Shortage to Persist into Q4 2024 Novo Nordisk Warns

Ozempic Shortage to Persist into Q4 2024, Novo Nordisk Warns

Novo Nordisk (NYSE: NVO) said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.

In a note published by the European Medicines Agency (EMA) on Monday, the obesity drug maker recommended healthcare workers continue limiting treatment initiation of new patients on Ozempic and its other diabetic drug, Victoza, until the supply situation improves.

(Source: ReutersReuters)

author avatar
Edward Cooke
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.